MEDISTIM ASA (MEDI.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:MEDI - NO0010159684 - Common Stock
251 NOK
+11 (+4.58%)
MEDI gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 63 industry peers in the Health Care Equipment & Supplies industry. MEDI has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. MEDI is valued quite expensive, but it does show an excellent growth. With these ratings, MEDI could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year MEDI was profitable.
MEDI had a positive operating cash flow in the past year.
Each year in the past 5 years MEDI has been profitable.
Each year in the past 5 years MEDI had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 24.76%, MEDI belongs to the top of the industry, outperforming 96.83% of the companies in the same industry.
The Return On Equity of MEDI (34.02%) is better than 96.83% of its industry peers.
Looking at the Return On Invested Capital, with a value of 30.97%, MEDI belongs to the top of the industry, outperforming 98.41% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MEDI is significantly above the industry average of 9.33%.
The 3 year average ROIC (24.89%) for MEDI is below the current ROIC(30.97%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.76% | ||
| ROE | 34.02% | ||
| ROIC | 30.97% |
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
1.3 Margins
The Profit Margin of MEDI (21.30%) is better than 90.48% of its industry peers.
In the last couple of years the Profit Margin of MEDI has remained more or less at the same level.
MEDI's Operating Margin of 26.88% is amongst the best of the industry. MEDI outperforms 93.65% of its industry peers.
MEDI's Operating Margin has been stable in the last couple of years.
MEDI has a better Gross Margin (81.21%) than 93.65% of its industry peers.
In the last couple of years the Gross Margin of MEDI has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.88% | ||
| PM (TTM) | 21.3% | ||
| GM | 81.21% |
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDI is creating value.
Compared to 1 year ago, MEDI has about the same amount of shares outstanding.
Compared to 5 years ago, MEDI has more shares outstanding
Compared to 1 year ago, MEDI has a worse debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of MEDI is 0.11, which is an excellent value as it means it would take MEDI, only 0.11 years of fcf income to pay off all of its debts.
MEDI's Debt to FCF ratio of 0.11 is amongst the best of the industry. MEDI outperforms 96.83% of its industry peers.
MEDI has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, MEDI belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.11 | ||
| Altman-Z | N/A |
ROIC/WACC3.63
WACC8.54%
2.3 Liquidity
MEDI has a Current Ratio of 3.33. This indicates that MEDI is financially healthy and has no problem in meeting its short term obligations.
MEDI has a better Current ratio (3.33) than 85.71% of its industry peers.
A Quick Ratio of 2.03 indicates that MEDI has no problem at all paying its short term obligations.
MEDI has a better Quick ratio (2.03) than 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.33 | ||
| Quick Ratio | 2.03 |
3. Growth
3.1 Past
MEDI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.36%, which is quite impressive.
Measured over the past 5 years, MEDI shows a small growth in Earnings Per Share. The EPS has been growing by 7.96% on average per year.
Looking at the last year, MEDI shows a very strong growth in Revenue. The Revenue has grown by 22.21%.
MEDI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.12% yearly.
EPS 1Y (TTM)40.36%
EPS 3Y4.41%
EPS 5Y7.96%
EPS Q2Q%48.5%
Revenue 1Y (TTM)22.21%
Revenue growth 3Y9.6%
Revenue growth 5Y9.12%
Sales Q2Q%25.68%
3.2 Future
The Earnings Per Share is expected to grow by 11.78% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.00% on average over the next years. This is quite good.
EPS Next Y16.97%
EPS Next 2Y13.46%
EPS Next 3Y11.78%
EPS Next 5YN/A
Revenue Next Year17.55%
Revenue Next 2Y12.56%
Revenue Next 3Y11%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MEDI is valuated quite expensively with a Price/Earnings ratio of 32.22.
The rest of the industry has a similar Price/Earnings ratio as MEDI.
The average S&P500 Price/Earnings ratio is at 26.31. MEDI is valued slightly more expensive when compared to this.
A Price/Forward Earnings ratio of 32.13 indicates a quite expensive valuation of MEDI.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDI is on the same level as its industry peers.
MEDI's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.22 | ||
| Fwd PE | 32.13 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MEDI is on the same level as its industry peers.
MEDI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. MEDI is cheaper than 77.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.1 | ||
| EV/EBITDA | 21.51 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDI does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of MEDI may justify a higher PE ratio.
PEG (NY)1.9
PEG (5Y)4.05
EPS Next 2Y13.46%
EPS Next 3Y11.78%
5. Dividend
5.1 Amount
MEDI has a Yearly Dividend Yield of 2.50%.
MEDI's Dividend Yield is rather good when compared to the industry average which is at 2.22. MEDI pays more dividend than 84.13% of the companies in the same industry.
MEDI's Dividend Yield is comparable with the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.5% |
5.2 History
The dividend of MEDI is nicely growing with an annual growth rate of 14.87%!
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
MEDI's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DPN/A
EPS Next 2Y13.46%
EPS Next 3Y11.78%
OSL:MEDI (11/28/2025, 7:00:00 PM)
251
+11 (+4.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners60.12%
Inst Owner ChangeN/A
Ins Owners2.83%
Ins Owner ChangeN/A
Market Cap4.60B
Revenue(TTM)668.61M
Net Income(TTM)142.42M
Analysts82.5
Price Target265.2 (5.66%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.5% |
Yearly Dividend4.5
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.96%
PT rev (3m)1.96%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.22 | ||
| Fwd PE | 32.13 | ||
| P/S | 6.88 | ||
| P/FCF | 24.1 | ||
| P/OCF | 24.1 | ||
| P/B | 11 | ||
| P/tB | 13.25 | ||
| EV/EBITDA | 21.51 |
EPS(TTM)7.79
EY3.1%
EPS(NY)7.81
Fwd EY3.11%
FCF(TTM)10.42
FCFY4.15%
OCF(TTM)10.42
OCFY4.15%
SpS36.46
BVpS22.82
TBVpS18.94
PEG (NY)1.9
PEG (5Y)4.05
Graham Number63.25
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.76% | ||
| ROE | 34.02% | ||
| ROCE | 40.19% | ||
| ROIC | 30.97% | ||
| ROICexc | 47.84% | ||
| ROICexgc | 63.44% | ||
| OM | 26.88% | ||
| PM (TTM) | 21.3% | ||
| GM | 81.21% | ||
| FCFM | 28.57% |
ROA(3y)20.73%
ROA(5y)20.96%
ROE(3y)26.96%
ROE(5y)27.52%
ROIC(3y)24.89%
ROIC(5y)25.57%
ROICexc(3y)39.99%
ROICexc(5y)39.99%
ROICexgc(3y)48.52%
ROICexgc(5y)48.01%
ROCE(3y)32.29%
ROCE(5y)33.19%
ROICexgc growth 3Y-6.52%
ROICexgc growth 5Y0.36%
ROICexc growth 3Y-8.47%
ROICexc growth 5Y0.04%
OM growth 3Y-5.05%
OM growth 5Y-1.15%
PM growth 3Y-4.63%
PM growth 5Y-0.92%
GM growth 3Y1.08%
GM growth 5Y0.46%
F-Score6
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.11 | ||
| Debt/EBITDA | 0.1 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 93.53% | ||
| Profit Quality | 134.12% | ||
| Current Ratio | 3.33 | ||
| Quick Ratio | 2.03 | ||
| Altman-Z | N/A |
F-Score6
WACC8.54%
ROIC/WACC3.63
Cap/Depr(3y)105.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.78%
Cap/Sales(5y)N/A
Profit Quality(3y)91.83%
Profit Quality(5y)103.03%
High Growth Momentum
Growth
EPS 1Y (TTM)40.36%
EPS 3Y4.41%
EPS 5Y7.96%
EPS Q2Q%48.5%
EPS Next Y16.97%
EPS Next 2Y13.46%
EPS Next 3Y11.78%
EPS Next 5YN/A
Revenue 1Y (TTM)22.21%
Revenue growth 3Y9.6%
Revenue growth 5Y9.12%
Sales Q2Q%25.68%
Revenue Next Year17.55%
Revenue Next 2Y12.56%
Revenue Next 3Y11%
Revenue Next 5YN/A
EBIT growth 1Y40.96%
EBIT growth 3Y4.07%
EBIT growth 5Y7.86%
EBIT Next Year34.29%
EBIT Next 3Y15.73%
EBIT Next 5YN/A
FCF growth 1Y81.09%
FCF growth 3Y-0.65%
FCF growth 5Y12.16%
OCF growth 1Y81.09%
OCF growth 3Y3.75%
OCF growth 5Y12.23%
MEDISTIM ASA / MEDI.OL FAQ
What is the ChartMill fundamental rating of MEDISTIM ASA (MEDI.OL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDI.OL.
What is the valuation status of MEDISTIM ASA (MEDI.OL) stock?
ChartMill assigns a valuation rating of 3 / 10 to MEDISTIM ASA (MEDI.OL). This can be considered as Overvalued.
Can you provide the profitability details for MEDISTIM ASA?
MEDISTIM ASA (MEDI.OL) has a profitability rating of 9 / 10.
What is the valuation of MEDISTIM ASA based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MEDISTIM ASA (MEDI.OL) is 32.22 and the Price/Book (PB) ratio is 11.
Can you provide the expected EPS growth for MEDI stock?
The Earnings per Share (EPS) of MEDISTIM ASA (MEDI.OL) is expected to grow by 16.97% in the next year.